Drugs / TENIVAC
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02673255 | Aug 2016 → Jul 2019 | — | Biomat USA, Inc. | Completed | No outcome recorded |
| Phase 42 trials · 1 missed | ||||||
| Phase 4 | NCT06588530 | Nov 2024 → Jan 2025 | autoinflammatory syndrome, diphtheria, tetanus | Rutgers, The State University of New Jersey | Completed | Missed primary |
| Phase 4 | NCT01439165 | Nov 2011 → Dec 2015 | diphtheria, pertussis, tetanus | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tenivac | “Tetanus and Diphtheria (Td) Vaccine, Manufacturer: Sanofi Pasteur (Tenivac), Dose: 0.5 mL, Route: Intramuscular (IM) in the deltoid muscle, Frequency: Every 90 days, Duration:...” NCT02673255 ↗2“Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (TENIVAC) vaccine” NCT01439165 ↗ |
| Modality | Vaccine | “Tetanus and Diphtheria Toxoids Adsorbed For Adult Use (TENIVAC) vaccine” NCT01439165 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT01439165 ↗ |